People · Operator
Named in public records as an officer, director or promoter · active 2013–2013 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Singulex Inc | — | Biotechnology | Series B | $44.7M | $483.8M | 2013 |
R. Douglas K. Norby at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside R. Douglas K. Norby on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Gregory Johnson | 1 | 8 |
| CARL L. GORDON | 1 | 7 |
| Heiner Dreismann | 1 | 6 |
| Hironori Hozoji | 1 | 4 |
| Gregory R. Johnson | 1 | 3 |
| Stephen Rose | 1 | 3 |
| Stephen L. Rose | 1 | 2 |
| Fred Vogt | 1 | 1 |
| Andre Marion | 1 | 1 |
| Philippe Goix | 1 | 1 |
| Heiner J. Dreismann | 1 | 1 |
| Philippe J. Goix | 1 | 1 |
| Michael K. Bell | 1 | 1 |
| Andre R. Marion | 1 | 1 |
| Guido L. Baechler | 1 | 1 |
| Fred K. Vogt | 1 | 1 |
| Hironori L. Hozoji | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.